Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes For the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks in TRANSCEND-T2D-1 Participants taking retatrutide 12 mg lost an average of 36.6 lbs (16.8%) No weight loss plateau was observed with retatrutide, with participants continuing their weight loss trajectory through 40 weeks 1,2 For the primary endpoint, participants taking retatrutide achieved average A1C reductions of up to 2.0%, using the efficacy estimand
For these reasons, we prefer injecting B12 into fat
At Claya, weve helped countless clients navigate the world of GLP-1s
doi: 10.3390/medicina57070669
If you inject a new dose too soon after the last one, the concentration of semaglutide in your body may peak at a level higher than intended
Semaglutide is also available as an oral pill, which may help those who are averse to injections